GT Biopharma falls on CEO, CFO departure
08/11/2021 15:58
** Drug developer's shares GTBP.O fall 34.5% to $4.51
** Co says Chairman and Chief Executive Officer Anthony
Cataldo and Chief Financial Officer Michael Handelman are
stepping down to pursue other interests urn:newsml:reuters.com:*:nPn4w1Bf8a
** Co names Gregory Berk appointed as interim CEO and Gavin
Choy as acting CFO
** GTBP starts process to identify individuals for permanent
positions for both roles
** Co is developing cancer therapies based on its
proprietary TriKE platform, which harnesses cancer killing
abilities of a patient's immune system's natural killer cells
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))